At a Glance

Other earnings, excluding one-time gains or charges unless noted, include:

* Anheuser-Busch Cos. said first-quarter profit rose 13% to $394.4 million, or 43 cents a share, in line with forecasts, as it raised prices and boosted sales of its Budweiser, Michelob and other beers. Revenue was up 6% to $2.98 billion.

* Boston Scientific Corp.’s profit fell 22% to $83 million, or 21 cents a share, missing analyst expectations by 3 cents. Sales fell 3.7% to $654 million as the company lost share in the market for stents, the tiny metal-mesh tubes used to prop open arteries cleared in angioplasty procedures.

* Chiron Corp. said first-quarter operating profit declined 5.7% to $37.8 million, or 19 cents a share, 2 cents better than expectations, as revenue rose 20% to $260 million.

* Ivax Corp. said operating profit nearly doubled to $50.8 million, or 31 cents a share, from $26.7 million, or 17 cents a share, a year earlier, helped by acquisitions and sales of the drug maker’s generic version of Bristol-Myers Squibb Co.’s cancer therapy Taxol. Analysts were expecting 26 cents. Sales rose 42% to $259.9 million.

* Sara Lee Corp. said fiscal third-quarter net income fell 8% to $241 million, or 28 cents a share, hurt by lower sales of underwear and hosiery. Revenue rose 3.2% to $4.31 billion at Sara Lee, whose products include baked goods, Hanes underwear and Jimmy Dean meats. The results were a penny better than analysts expected.